Proven • Personalized • Precise

Cesium Blu™ – a proven, minimally invasive treatment designed to treat a variety of cancers with precision.

A diagnosis is the first step towards treating your cancer.
With the many advances and options in cancer treatment, determining what is right for you can feel overwhelming.

Isoray is here to help.

We’re committed to providing a powerful, proven treatment while connecting you with the very best care teams available.

Isoray - Proven, Personalized, Precise

Patients & Families

Find a Doctor Near You

A diagnosis is just the first step toward treating your cancer. We are here to help you make an informedtreatment decision with your doctor so you can begin living your life again.

Don't let cancer slow you down!
Couple enjoying life!
Time with family and grandchildren is precious!
Cesium Blu - logo

Brachytherapy with Cesium Blu™

an isotope like none other.

Years of Data

Patients Treated

Day Half Life

Targets Cancer

Treats cancer at the source

High Energy

Higher energy, greater coverage

Short Half-Life

Shorter half-life for rapid resolution of side-effects

Quick recovery time for most patients

Quick recovery time for most patients

Isoray with Cesium-131 can treat Prostate, Head and Neck, Lung, Brain and Gynaecological cancers

“Cesium provides everything we want for prostate brachytherapy as both a monotherapy and in combination therapy, including delivery of a high dose of radiation more quickly for high risk patients in a low dose rate ‘setting.’” 

Dr. Bernard W. Taylor

Texas Oncology - Longview Cancer Center

About Us

Isoray develops innovative, personalized brachytherapy products that effectively treat many forms of cancer.

Looking Ahead

Looking Ahead

By CEO Lori Woods This is my first blog post, and it comes during a year that has changed how we communicate, how we work, and virtually every aspect of our lives. COVID-19 has challenged us and changed us. We hope for better days ahead even as we face the reality of a pandemic that still challenges us and many unknowns and uncertainties that remain. The one constant we can point to with ...

Blog: Patient Stories


Press Releases

Isoray Announces First Quarter Fiscal 2022 Financial Results

Isoray Announces First Quarter Fiscal 2022 Financial Results

Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and...

Whether you’re a Patient or a Clinician,
we’re here to help.

Call us at 1-509-375-5329